Immunome, Inc. logo IMNM - Immunome, Inc.

NEXT EARNINGS: Mar 18, 2026 (in 21 days) EPS Est: $-0.65 | Rev Est: $784620
Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 9
HOLD 0
SELL 0
STRONG
SELL
0
| PRICE TARGET: $35.29 DETAILS
HIGH: $40.00
LOW: $26.00
MEDIAN: $36.00
CONSENSUS: $35.29
UPSIDE: 59.54%
Market Cap: 2.03B
Volume: 551,829
Avg Volume: 2,080,900
52 Week Range: 5.15-27.65
Sector: Healthcare
Industry: Biotechnology
Beta: 2.11
Last Dividend: $N/A
Exchange: NASDAQ
Country: US
Employees: 131
IPO Date: 2020-10-02
EPS (TTM): -5.00
P/E Ratio: -2.13
Revenue (TTM): 9.04M
Total Assets: 240.24M
Total Debt: 4.83M
Cash & Equiv: 143.35M
Rev Growth (5Y): -35.5%
EPS Growth (5Y): N/A
FCF Growth (5Y): N/A
ROCE: -82.5%
Debt/Equity: 0.03

Earnings History

Date EPS Actual EPS Est EPS Surprise Rev Actual Rev Est Rev Surprise
2025-11-06 $-0.65 $-0.57 -14.0% $850000
2025-08-06 $-0.50 $-0.52 +3.8% $4.0M $833333 +381.8%
2025-05-12 $-0.52 $-0.66 +21.2% $2.9M $457140 +540.1%
2025-03-19 $-0.84 $-0.68 -23.5% $2.7M $3.1M -13.0%
2024-11-13 $-0.78 $-0.60 -30.0% $2.9M $3.2M -7.8%
2024-08-12 $-0.49 $-0.38 -28.9% $2.4M $2.5M -7.3%
2024-05-14 $-0.34 $-0.80 +57.5% $1.0M $2.8M -63.3%
2024-03-28 $-0.54 $-0.28 -92.9% $3.8M $2.1M +85.1%

Track Record

Statements >
Metric 2024 2023 2022 2021 2020 2019 2018
Revenue 9.04M 14.02M 0 0 0 0 0
Net Income (292.96M) (106.81M) (36.90M) (24.71M) (17.84M) (10.55M) (7.84M)
EPS -5.00 -5.38 -3.09 -2.14 -1.69 -1.84 -7.18
Total Assets 240.24M 148.54M 24.05M 57.92M 44.52M 5.06M 4.45M
Total Debt 4.83M 1.65M 291,000 317,000 613,000 564,000 1.18M
Cash & Equivalents 143.35M 98.68M 20.32M 49.23M 39.77M 2.54M 1.60M
Operating Cash Flow (110.79M) (7.57M) (28.69M) (18.23M) (12.13M) (9.60M) (7.41M)
Free Cash Flow (164.30M) (8.40M) (28.94M) (18.30M) (12.72M) (9.83M) (7.63M)
FCF per Share -2.80 -0.42 -2.39 -1.59 -1.26 -1.71 -6.99
Book Value 181.16M 119.88M 16.65M 48.19M 41.34M (35.63M) (25.20M)
Cash & ST Investments 217.30M 138.14M 20.32M 49.23M 39.77M 2.54M 1.60M
ROC Equity -1.62 -0.89 -2.22 -0.51 -0.43 N/A N/A